Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.
about
Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replicationPrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesSurveillance system for hepatitis C infection: A practical approachSystematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis.Trends in the prevalence of thrombocytopenia among individuals infected with hepatitis C virus in the United States, 1999-2008Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQHepatitis C virus proteins activate NRF2/ARE pathway by distinct ROS-dependent and independent mechanisms in HUH7 cells.Deficiency of the promyelocytic leukemia protein fosters hepatitis C-associated hepatocarcinogenesis in miceCurrent and future disease progression of the chronic HCV population in the United States.Identification of HNRNPK as regulator of hepatitis C virus particle production.A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deteriorationPathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index.LRRFIP1 Inhibits Hepatitis C Virus Replication by Inducing Type I Interferon in HepatocytesIntravenous drug use and hepatitis C virus in iranHepatitis C virus-induced hepatocellular carcinomaActivation of Type I and III Interferon Response by Mitochondrial and Peroxisomal MAVS and Inhibition by Hepatitis C Virus.Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation.Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.Nonprimate hepaciviruses in domestic horses, United kingdomGlobal control of hepatitis C: where challenge meets opportunityOverview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.Use of HOMA-IR in hepatitis C.Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents.The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity.Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C.A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin.Serum models accurately predict liver-related clinical outcomes in chronic hepatitis C.Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.Unconjugated interferon-stimulated gene 15 specifically interacts with the hepatitis C virus NS5A protein via domain I.Racial diversity in mortality and morbidity in urban patients with hepatitis C.Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination.Aspartic acid based nucleoside phosphoramidate prodrugs as potent inhibitors of hepatitis C virus replication.Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C-A Reappraisal from a Tertiary Care Center in Northern India.Genomic variants link to hepatitis C racial disparities.A key problem and challenge for hepatology: Obesity-related metabolic liver diseases.Clinical outcomes of chronic hepatitis C patients related to baseline liver fibrosis stage: a hospital-based linkage study.
P2860
Q27339861-EE4166E3-C2AF-4235-93C4-B913EE627D28Q28272678-6403A276-7DA4-4F48-9862-E1C31FC87033Q28386462-A6A98102-47E4-4B47-B040-F9F06E4DC551Q30399476-E63EE519-9094-421A-A1B2-04F325056047Q33400231-6310E0A4-1F49-45E5-9BD0-568F67637B29Q33813860-7AA313E5-ED22-4556-87F0-25CEDD55C7CAQ34024112-90985979-C002-4447-9EC2-9CCDC1F0F4C6Q34415922-D8BD0A3E-3605-48E3-AA79-1E7060DB6E5BQ34737843-3FE27D09-2A0F-48D2-8FD0-5FCA82C56BB9Q34875666-29786249-A6A5-4A76-B3F2-01E952145CABQ35107005-167D0ABF-CB06-48A8-8DEB-CADDBF9DAA18Q35619104-420CCDEF-9D84-4E52-B655-18391919EB7DQ35668307-92614D12-80EF-4491-BC68-2BFDB26445F8Q35671655-2051387C-2C2D-4678-8570-CCA079FA581EQ35819891-07D0CEDB-720F-45B9-B336-D93527A57B7DQ35824057-CC8661CE-E1C1-42AA-900F-8C5DC0694AA2Q35847364-1425119A-1819-4C61-9DC4-6C38B41EE0D1Q35862839-3F4BD8BE-7D5F-4101-976C-0B6DE27ED607Q36118056-2732AE0A-95AE-4DA4-9DAE-DDA786000849Q36306768-D078561E-8E32-4358-A4FF-D43837CB6427Q36570546-BBF58216-F690-44A2-8276-13A9D3FC9EC4Q37077112-4430B8C9-5300-4BAC-AC95-4D4A0B9B1FD7Q37818336-0718776B-7FE8-49A3-830C-8979B73456D0Q37931383-1857E3F1-7C65-40E0-8DEC-66F4E116759DQ38016958-710B684B-48FC-4E49-A808-FAEF502B1E9FQ38113079-D0C358FA-F9E5-4588-A25E-C5D44618A6A1Q38482765-5AB657BA-CDCA-4EAD-9F13-49602296D575Q38726664-800BB384-703D-49D3-B368-A8371AF15752Q39515356-026A8994-E0F7-4C9B-B29A-AC0FB5E311A5Q39945747-2E808083-52D7-436D-B763-15BE78D37B53Q40098679-7F81A783-68D4-41C6-81BA-B38E9D79A572Q40185810-1BA28ACF-2F26-45A2-8C54-2DDA8D1E7EF2Q40348098-5158B6CD-2802-4EB9-90D7-F03CFACF9430Q40588090-14F2BD39-3A49-497B-BAF8-84CDDE2AE91CQ41106565-25A19079-E914-4785-BA9A-2969FB2C199CQ41147723-69F0DB03-EA25-40FA-8C7B-9CD98079248EQ41258033-B70201E5-DA92-43A5-90A9-4AB50CF13E4BQ41708713-7843509E-4F54-4382-964C-EE4E5026F281Q41771407-E86FF19E-0CED-41A5-B039-576843C2C93FQ42182165-8EF81066-818A-4083-B7C7-65933D9B85C4
P2860
Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prevalence and challenges of l ...... c hepatitis C virus infection.
@en
Prevalence and challenges of l ...... c hepatitis C virus infection.
@nl
type
label
Prevalence and challenges of l ...... c hepatitis C virus infection.
@en
Prevalence and challenges of l ...... c hepatitis C virus infection.
@nl
prefLabel
Prevalence and challenges of l ...... c hepatitis C virus infection.
@en
Prevalence and challenges of l ...... c hepatitis C virus infection.
@nl
P2093
P1476
Prevalence and challenges of l ...... c hepatitis C virus infection.
@en
P2093
Christian Trépo
Francesco Negro
Gary L Davis
Hashem El-Serag
Ira M Jacobson
P304
924-33; quiz e117
P356
10.1016/J.CGH.2010.06.032
P407
P577
2010-08-14T00:00:00Z